Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
RESEARCH TOOLSreports
Holding ABOS?
Track your performance easily
Earnings Data
Report Date
Mar 31, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.49Last Year’s EPS
-$0.28Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -42.55%
|Next Earnings Date:Mar 31, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with rapid progress in clinical trials, strong financial management, and strategic leadership appointments, although it acknowledges increased R&D expenses and a net loss.Company Guidance
During the Acumen Pharmaceuticals Q3 2024 earnings call, the company provided detailed guidance on its financial outlook and clinical trial progress. The company reported having approximately $259 million in cash and marketable securities as of September 30, 2024, with an anticipated cash runway extending into the first half of 2027. R&D expenses for the quarter were $27.2 million, primarily driven by the ALTITUDE-AD trial, which is evaluating the A beta oligomer-targeted antibody sabirnetug in early Alzheimer's patients. Enrollment for this Phase II study, targeting 540 patients, is progressing faster than expected, with completion anticipated in the first half of 2025. The company also discussed its ongoing Phase I study of subcutaneous sabirnetug, with top-line results expected in Q1 2025. Additionally, Acumen is leveraging its plasma phospho-tau 217 assay for more efficient patient selection in clinical trials. Despite a quarterly net loss of $29.8 million, the company remains focused on advancing sabirnetug's development and maintaining strong financial health.Rapid Enrollment in ALTITUDE-AD Trial
Enrollment in the Phase II ALTITUDE-AD trial has progressed faster than expected, with more than 75 sites active and enrolling across North America, the U.K., and the EU. Completion of enrollment is anticipated in the first half of 2025.
Successful Use of Blood-Based Biomarkers
The use of the plasma phospho-tau 217 assay has improved the screening process for the ALTITUDE-AD trial, reducing unnecessary procedures by about 50% compared to the Phase I study.
Strong Financial Position
Acumen has approximately $259 million in cash and marketable securities, with an expected cash runway lasting into the first half of 2027.
New Appointment to Strengthen Leadership
Dr. Amy Schacterle has been appointed as Chief Regulatory Officer and Head of Quality, bringing over 30 years of experience in regulatory affairs and quality assurance.
---
ABOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ABOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $3.22 | $2.68 | -16.77% |
| Aug 13, 2024 | $2.56 | $2.77 | +8.20% |
| May 14, 2024 | $3.36 | $3.69 | +9.82% |
| Mar 26, 2024 | $4.25 | $3.75 | -11.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Acumen Pharmaceuticals (ABOS) report earnings?
Acumen Pharmaceuticals (ABOS) is schdueled to report earning on Mar 31, 2025, TBA Not Confirmed.
What is Acumen Pharmaceuticals (ABOS) earnings time?
Acumen Pharmaceuticals (ABOS) earnings time is at Mar 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABOS EPS forecast?
ABOS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.49.
---